Fig. 4
From: Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy
Re-sensitization to vemurafenib involves lipid peroxidation. a Oleate (20 μM) or a mixture of linoleate (10 μM) + linolenate (10 μM) was added to the culture medium of 451lu R SREBP+/− cells and 451lu R cells treated with either vemurafenib alone or a combination with fatostatin or betulin, raw images and bar graph are shown in Supplementary Figs. 23, 24 (n = 3). b Mitochondrial superoxide levels in 451lu R cells treated with vemurafenib and fatostatin; medium was supplemented with oleate or linoleate + linolenate (n = 3). c MDA levels normalized to protein content in 451lu R cells (n = 5). d Effect of alpha-tocopherol, ferrostatin and NAC supplementation on proliferation curves of 451lu R cells treated with vemurafenib + fatostatin, raw images and bar graph are shown in Supplementary Figs. 26, 27 (n = 4). e Proliferation curves of the therapy-sensitive cell lines M229 and 451lu treated with vemurafenib, alpha-tocopherol, ferrostatin, and NAC (phase contrast density measured by the Incucyte system) raw images and bar graph are shown in Supplementary Figs. 30, 31 (n = 3). All data are represented as mean ± s.e.m. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)
